Role of Positron Emission Tomography in Lymphoma

This publication has 15 references indexed in Scilit:

• Response Assessment of Aggressive Non-Hodgkin’s Lymphoma by Integrated International Workshop Criteria and Fluorine-18–Fluorodeoxyglucose Positron Emission Tomography
  Journal of Clinical Oncology, 2005
• Intensity of¹⁸Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin’s Lymphoma
  Journal of Clinical Oncology, 2005
• Comparison between 2-deoxy-2-[18F]fluoro-D-Glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma
  Molecular Imaging & Biology, 2004
• Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer
  European Journal of Nuclear Medicine and Molecular Imaging, 2004
• FDG-PET/CT in re-staging of patients with lymphoma
  European Journal of Nuclear Medicine and Molecular Imaging, 2003
• Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease
  Annals of Oncology, 2003
• Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma
  Annals of Oncology, 2002
• Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([¹⁸F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is [¹⁸F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?
  Journal of Clinical Oncology, 2001
• Whole-body 18F-FDG PET for the evaluation of patients with Hodgkinʼs disease and non-Hodgkinʼs lymphoma
  Nuclear Medicine Communications, 1999
• Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
  Radiology, 1997